The gut doesn’t lie. You can ace the fellowship at UT Southwestern, pick up an executive program at MIT, and still learn the hard way that health starts with what’s happening in your microbiome. That’s the story behind Resbiotic Nutrition, Inc., founded in 2020 by physician-scientist Dr. C. Vivek Lal, MD, FAAP in Birmingham, Alabama. He’s not just the Founder and CEO, he’s also Director of the Pulmonary Microbiome Lab at the University of Alabama at Birmingham and Director of Clinical Innovation at the Marnix Heersink Institute for Biomedical Innovation. In other words, he’s not dabbling in probiotics, he’s building a company on a decade of NIH-funded science.
Resbiotic just announced it has raised $14.5 million in total funding, with the latest $8 million Series A backed by Sororibus Capital and Biostack Ventures. Earlier rounds stacked like disciplined lifts: a $3 million seed led by Timberline Holdings in April 2021, $2.64 million in February 2024, and another $1.5 million in February 2025. Add it up, and you’ve got capital matched to conviction.
Conviction matters because the results are hard to argue with. Over 400 percent year-over-year sales growth since 2022. Nationwide launches at Walmart in March 2025 and GNC in June 2024. A direct-to-consumer platform humming in parallel with international expansion through Laboratorios Columbia in Mexico. Clinical data that reads like the scoreboard of a team playing in a different league: 95 percent of participants ready to recommend resB, 82 percent reporting quality-of-life gains, 400 percent GLP-1 increases in preclinical human cell studies, and double, and triple-digit boosts in probiotics and hormone production.
This is a company building around its Gut-X Axis platform, leveraging probiotics, prebiotics, postbiotics, and botanicals to connect gut health to outcomes in respiratory, metabolic, and systemic wellness. The flagship resB Lung Support Probiotic is the world’s first clinically tested probiotic targeting the gut-lung axis. Add resG prebeet ENERGY and resM GLP-1 Postbiotic, and you see how a consumer portfolio doubles as a research engine.
Resbiotic’s leadership blends science and scale. Alongside Dr. C. Vivek Lal, Chief Medical Officer Amit Gaggar, MD, PhD, Director of Partnerships Kara Siedman, RD, CDCES, and Director of Lab Operations Teodora Thea Nicola, MD, PhD, MBA push execution. Scott Bush drives strategy. And with advisors like Dr. Namasivayam Ambalavanan of UAB and Dr. Yvonne Huang of Michigan, there’s no risk of the science bending to the marketing.
Congratulations to Dr. C. Vivek Lal and the team for proving the microbiome isn’t niche, it’s the future. Sororibus Capital, Biostack Ventures, Timberline Holdings, First Avenue Ventures, and UAB backed it early. Now the market gets to catch up.
